Treace Medical Concepts, Inc. (TMCI)
| Market Cap | 178.40M -61.3% |
| Revenue (ttm) | 207.32M -1.7% |
| Net Income | -61.04M |
| EPS | -0.96 |
| Shares Out | 64.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 946,222 |
| Open | 2.640 |
| Previous Close | 2.660 |
| Day's Range | 2.569 - 2.810 |
| 52-Week Range | 1.170 - 7.780 |
| Beta | 1.11 |
| Analysts | Hold |
| Price Target | 4.00 (+45.46%) |
| Earnings Date | May 8, 2026 |
About TMCI
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percupla... [Read more]
Financial Performance
In 2025, Treace Medical Concepts's revenue was $212.69 million, an increase of 1.59% compared to the previous year's $209.36 million. Losses were -$59.00 million, 5.85% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $4.0, which is an increase of 45.46% from the latest price.
News
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on ...
Treace Medical Concepts Earnings Call Transcript: Q1 2026
Q1 2026 saw a 10% revenue decline due to lower-priced product mix, but case volumes grew mid-single digits and gross margins remained strong. New product adoption is accelerating, with guidance reaffirmed for improved performance and revenue growth in Q4 2026.
Treace Medical Concepts Earnings release: Q1 2026
Treace Medical Concepts released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Treace Medical Concepts Quarterly report: Q1 2026
Treace Medical Concepts has published its Q1 2026 quarterly earnings report on May 8, 2026.
Treace Medical Concepts Reports First Quarter 2026 Financial Results
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical...
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgic...
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition tap...
Treace Medical Concepts Proxy statement: Proxy filing
Treace Medical Concepts filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Treace Medical Concepts Proxy statement: Proxy filing
Treace Medical Concepts filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Treace Medical price target lowered to $2 from $3 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Treace Medical (TMCI) to $2 from $3 and keeps a Hold rating on the shares. The company’s Q4 saw negative…
Treace Medical price target lowered to $2.25 from $2.50 at UBS
UBS lowered the firm’s price target on Treace Medical (TMCI) to $2.25 from $2.50 and keeps a Neutral rating on the shares.
Treace Medical price target lowered to $7 from $7.50 at Lake Street
Lake Street lowered the firm’s price target on Treace Medical (TMCI) to $7 from $7.50 and keeps a Buy rating on the shares. Treace’s Q4 was slightly favorable to preliminary…
Treace Medical Concepts Earnings Call Transcript: Q4 2025
Revenue declined 9% in Q4 2025 due to product mix, but case volumes and adjusted EBITDA improved. 2026 guidance anticipates flat to -6% revenue, with growth expected in Q4 from new product launches and continued cost reductions.
Treace Medical Concepts Annual report: Q4 2025
Treace Medical Concepts has published its Q4 2025 annual report on February 27, 2026.
Treace Medical Concepts Earnings release: Q4 2025
Treace Medical Concepts released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical to highlight new product innovations, present data at ACFAS
Treace Medical (TMCI) Concepts announced it will highlight new product innovations and present new interim data for the ALIGN3D, MTA3D, and SpeedMTP clinical studies at the American College of Foot…
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical Concepts Transcript: 44th Annual J.P. Morgan Healthcare Conference
Expanded to a comprehensive 3D bunion solutions portfolio, driving strong surgeon adoption and mid-single-digit procedure growth in late 2025. New MIS and fixation products are broadening market reach, while high gross margins and improved profitability position the company for continued growth in 2026.
Treace Medical Concepts Slides: 44th Annual J.P. Morgan Healthcare Conference
Treace Medical Concepts has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical reports completion of first Lapiplasty Lightning technology case
Treace Medical (TMCI) announced the successful completion of the first case utilizing its Lapiplasty Lightning technology.
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical price target lowered to $3 from $5 at Stifel
Stifel lowered the firm’s price target on Treace Medical (TMCI) to $3 from $5 and keeps a Hold rating on the shares. The firm, which argues that the 2026 setup…